NCT00792948 2026-03-18
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
40 trialsNCT02143414 2026-03-18
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03914625 2026-03-18
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06317662 2026-03-18
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07069699 2026-03-18
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT05397496 2026-03-17
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
Novartis
Phase 1 Active not recruiting
NCT07476729 2026-03-17
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
Charite University, Berlin, Germany
Phase 3 Not yet recruiting
NCT06561425 2026-03-16
Atalanta-1
Galapagos NV
Phase 1/2 Active not recruiting
NCT03876769 2026-03-13
CASSIOPEIA
Novartis
Phase 2 Active not recruiting
NCT05453500 2026-03-13
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
University of Washington
Phase 2 Recruiting
NCT06124157 2026-03-13
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06738368 2026-03-13
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
University of Washington
Phase 2 Recruiting
NCT07133997 2026-03-13
Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia
City of Hope Medical Center
Phase 1 Not yet recruiting
NCT01962636 2026-03-12
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Phase NA Recruiting
NCT05442515 2026-03-12
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT02723994 2026-03-11
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Incyte Corporation
Phase 2 Completed
NCT06395103 2026-03-11
MK-9999-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05537766 2026-03-10
ZUMA-25
Gilead Sciences
Phase 2 Terminated
NCT06343090 2026-03-10
Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
Beijing GoBroad Hospital
Phase NA Recruiting
NCT06326008 2026-03-09
Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
Beijing GoBroad Hospital
Phase 1 Recruiting
NCT05157971 2026-03-05
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
City of Hope Medical Center
Phase 1 Recruiting
NCT07109219 2026-03-04
ALLight
AstraZeneca
Phase 1/2 Recruiting
NCT03150693 2026-03-02
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Alliance for Clinical Trials in Oncology
Phase 3 Suspended
NCT06173518 2026-03-02
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Autolus Limited
Phase 1 Recruiting
NCT07078929 2026-03-02
CMD63
Chulalongkorn University
Phase 1 Recruiting
NCT04195633 2026-02-27
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT03504644 2026-02-25
Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
Eastern Cooperative Oncology Group
Phase 1/2 Active not recruiting
NCT06389305 2026-02-25
CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction
Beijing GoBroad Hospital
Phase NA Recruiting
NCT04739813 2026-02-24
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07429461 2026-02-24
Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT02981628 2026-02-23
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 2 Recruiting
NCT03007147 2026-02-23
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 3 Active not recruiting
NCT07153796 2026-02-23
A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03810196 2026-02-20
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
Children's Hospital of Philadelphia
Phase NA Recruiting
NCT05389423 2026-02-19
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06863259 2026-02-18
Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
Children's Hospital Medical Center, Cincinnati
Phase 1 Recruiting
NCT03136146 2026-02-17
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03441061 2026-02-17
Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04094311 2026-02-17
Study of Out of Specification for Tisagenlecleucel
Novartis
Phase 3 Recruiting
NCT07223021 2026-02-17
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
Phase 3 Recruiting